Journal Article Summary
The article examines the health characteristics and aspirin use among older adults who participated in the ASPirin in Reducing Events in the Elderly – eXTension (ASPREE-XT) observational study. This research is significant because previous findings from the ASPREE trial indicated that low-dose aspirin did not improve disability-free survival in healthy older adults. Understanding the health status of participants who continued into the observational phase can provide insights into the long-term effects of aspirin and the overall health trajectory of aging individuals.
The study involved 16,317 participants from the original ASPREE trial, with a mean age increase from 74.9 to 80.6 years at the baseline of ASPREE-XT. The researchers found that overall health and physical function had declined since the original trial, with more participants living alone and a higher prevalence of chronic conditions like kidney disease and diabetes. Interestingly, 8.7% of participants without a clear indication for aspirin use reported taking it regularly, which was consistent with pre-trial usage rates.
However, the study has limitations, including a potential bias in participant selection, as those who consented to continue were generally healthier than those who did not. This could affect the generalizability of the findings, particularly for minority populations, as there was a notable loss of U.S. participants during the transition to ASPREE-XT. Patients should discuss their aspirin use and any health concerns with their healthcare providers, especially in light of the current recommendations against routine aspirin use for primary prevention in older adults.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Ernst Michael E., Broder Jonathan C., Wolfe Rory, Woods Robyn L., Nelson Mark R., Ryan Joanne, Shah Raj C., Orchard Suzanne G., et al.. Health Characteristics and Aspirin Use in Participants at the Baseline of the ASPirin in Reducing Events in the Elderly – eXTension (ASPREE-XT) Observational Study. Contemporary clinical trials 2023. DOI: 10.1016/j.cct.2023.107231. PMID: 37196887. PMCID: PMC10330669.
Featured Pill Pals Product
OTC 1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
